Motexafin gadolinium: a novel radiosensitizer for brain tumors.

Article Details

Citation
Copy to clipboard

Forouzannia A, Richards GM, Khuntia D, Mehta MP

Motexafin gadolinium: a novel radiosensitizer for brain tumors.

Expert Rev Anticancer Ther. 2007 Jun;7(6):785-94.

PubMed ID
17555388 [ View in PubMed
]
Abstract

Despite advances in the field of oncology, progress for patients with brain metastases and most primary brain tumors has been slow. New efforts to enhance the therapeutic index of radiation therapy are under way, including the use of radiosensitizers. Motexafin gadolinium (Xcytrin) is one such novel agent with several unique properties that enhance the cytotoxic potential of radiation therapy, as well as several chemotherapeutic agents, and possibly has independent cytotoxicity in certain lymphoid malignancies. Motexafin gadolinium is very well tolerated with tumor specific uptake. The rationale for the use of this drug as well as its current and future role as a radiation enhancer in the management of brain tumors is reviewed.

DrugBank Data that Cites this Article

Drugs